Business Description
4D Molecular Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US35104E1001
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 20.21 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.15 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 2.38 | |||||
Beneish M-Score | -271.35 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -37 | |||||
3-Year EBITDA Growth Rate | 31.7 | |||||
3-Year EPS without NRI Growth Rate | 33.6 | |||||
3-Year FCF Growth Rate | 37.1 | |||||
3-Year Book Growth Rate | -9.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | -14.77 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.08 | |||||
9-Day RSI | 31.69 | |||||
14-Day RSI | 32.57 | |||||
6-1 Month Momentum % | -66.04 | |||||
12-1 Month Momentum % | -62.35 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 17.33 | |||||
Quick Ratio | 17.33 | |||||
Cash Ratio | 17.03 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.3 | |||||
Shareholder Yield % | -113.94 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -990447.06 | |||||
Net Margin % | -844000 | |||||
FCF Margin % | -686811.76 | |||||
ROE % | -30.15 | |||||
ROA % | -28.07 | |||||
ROIC % | -240.61 | |||||
ROC (Joel Greenblatt) % | -507.12 | |||||
ROCE % | -34.32 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5880 | |||||
PB Ratio | 0.55 | |||||
Price-to-Tangible-Book | 0.55 | |||||
EV-to-EBIT | 1.1 | |||||
EV-to-EBITDA | 1.14 | |||||
EV-to-Revenue | -10890 | |||||
EV-to-Forward-Revenue | 4.54 | |||||
EV-to-FCF | 1.59 | |||||
Price-to-Net-Current-Asset-Value | 0.65 | |||||
Price-to-Net-Cash | 0.67 | |||||
Earnings Yield (Greenblatt) % | 90.91 | |||||
FCF Yield % | -42.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FDMT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
4D Molecular Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.017 | ||
EPS (TTM) ($) | -2.85 | ||
Beta | 3.07 | ||
Volatility % | 107.17 | ||
14-Day RSI | 32.57 | ||
14-Day ATR ($) | 0.502811 | ||
20-Day SMA ($) | 6.91275 | ||
12-1 Month Momentum % | -62.35 | ||
52-Week Range ($) | 5.58 - 36.25 | ||
Shares Outstanding (Mil) | 46.23 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
4D Molecular Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
4D Molecular Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
4D Molecular Therapeutics Inc Frequently Asked Questions
What is 4D Molecular Therapeutics Inc(FDMT)'s stock price today?
When is next earnings date of 4D Molecular Therapeutics Inc(FDMT)?
Does 4D Molecular Therapeutics Inc(FDMT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |